key: cord-327287-e5k2gcse
authors: May, Jori E.; Siniard, Rance C.; Marques, Marisa
title: The challenges of diagnosing heparin‐induced thrombocytopenia in patients with COVID‐19
date: 2020-08-02
journal: Res Pract Thromb Haemost
DOI: 10.1002/rth2.12416
sha: 
doc_id: 327287
cord_uid: e5k2gcse

nan

To the Editor, Riker EIAs are sensitive, but not specific, for HIT diagnosis because they detect all anti-platelet factor 4 (PF4)/heparin antibodies, including those that are nonpathogenic. 3 In contrast, functional assays (including SRA) identify only antibodies with the pathogenic ability to activate platelets and therefore have increased specificity. 3 Given that severe COVID-19 is a hyperinflammatory state, it is plausible that the increased immunoreactivity also increases production of anti-PF4/heparin antibodies; however, they may not result in clinical HIT but may instead increase potential for false-positive EIAs.

Herein, we report our experience with hospitalized patients with 

The authors have no conflicts of interest to disclose. 

Heparin-induced thrombocytopenia with thrombosis in COVID-19 adult respiratory distress syndrome

COVID-19 and its implications for thrombosis and anticoagulation

Testing for heparin-induced thrombocytopenia antibodies